药品注册申请号:050627
申请类型:NDA (新药申请)
申请人:SANOFI AVENTIS US
申请人全名:SANOFI AVENTIS US LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 RIFADIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Yes Yes AP 1989/05/25 1989/05/25 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/10/10 SUPPL-37(补充) Approval Labeling STANDARD
2023/12/08 SUPPL-36(补充) Approval Labeling STANDARD
2023/08/16 SUPPL-35(补充) Approval Labeling STANDARD
2023/02/17 SUPPL-34(补充) Approval Labeling STANDARD
2023/02/10 SUPPL-33(补充) Approval Labeling STANDARD
2022/01/29 SUPPL-30(补充) Approval Labeling STANDARD
2021/10/21 SUPPL-29(补充) Approval Labeling STANDARD
2021/06/17 SUPPL-28(补充) Approval Labeling STANDARD
2020/05/12 SUPPL-27(补充) Approval Labeling STANDARD
2019/08/27 SUPPL-25(补充) Approval Labeling STANDARD
2019/02/28 SUPPL-23(补充) Approval Labeling STANDARD
2019/01/23 SUPPL-21(补充) Approval Labeling STANDARD
2018/01/08 SUPPL-20(补充) Approval Labeling STANDARD
2017/04/24 SUPPL-17(补充) Approval Labeling STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
2015/12/02 SUPPL-16(补充) Approval Manufacturing (CMC) STANDARD
2015/04/09 SUPPL-15(补充) Approval Manufacturing (CMC) STANDARD
2013/02/27 SUPPL-14(补充) Approval Labeling STANDARD
2010/11/10 SUPPL-12(补充) Approval Labeling STANDARD
2004/08/20 SUPPL-8(补充) Approval Labeling STANDARD
2000/04/12 SUPPL-7(补充) Approval Labeling STANDARD
2000/04/12 SUPPL-6(补充) Approval Labeling STANDARD
1996/09/17 SUPPL-4(补充) Approval Labeling STANDARD
1995/07/28 SUPPL-5(补充) Approval Manufacturing (CMC) STANDARD
1993/06/18 SUPPL-1(补充) Approval Labeling ;Orphan
1992/03/10 SUPPL-2(补充) Approval Labeling
1989/05/25 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD ;Orphan
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:RIFAMPIN 剂型/给药途径:INJECTABLE;INJECTION 规格:600MG/VIAL 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050627 001 NDA RIFADIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Prescription Yes Yes AP 1989/05/25 SANOFI AVENTIS US
064217 001 ANDA RIFAMPIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Prescription No No AP 1999/10/29 HIKMA
065421 001 ANDA RIFAMPIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Prescription No No AP 2008/05/22 MYLAN LABS LTD
065502 001 ANDA RIFAMPIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Prescription No No AP 2010/09/21 EPIC PHARMA LLC
091181 001 ANDA RIFAMPIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Prescription No No AP 2014/08/21 FRESENIUS KABI USA
205039 001 ANDA RIFAMPIN RIFAMPIN INJECTABLE;INJECTION 600MG/VIAL Prescription No No AP 2016/03/03 HIKMA PHARMS
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database